T

TG Therapeutics
D

TGTX

32.390
USD
0.19
(0.59%)
مفتوح الان
حجم التداول
7,654
الربح لكل سهم
0
العائد الربحي
-
P/E
-325
حجم السوق
5,065,349,968
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -0.81000
    (-9.54%)
    7.68000 USD
    C
    CRVS
    -0.41000
    (-8.18%)
    4.60000 USD
    I
    INCY
    0.150
    (0.22%)
    69.060 USD
    J
    JNCE
    0.08500
    (5.31%)
    1.68000 USD
    K
    KPTI
    -0.00430
    (-0.67%)
    0.64000 USD
    M
    MYOV
    0
    (0%)
    0.000000 USD
    P
    PBYI
    0.01500
    (0.54%)
    2.77000 USD
    المزيد
الأخبار

العنوان: TG Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.